Legend Biotech has managed to remove GenScript Biotech as its majority shareholder, just as the former parent’s Chinese background falls under a U.S. biosecurity microscope. After a financial maneuver ...
Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its 48% holding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results